

# Rodney J Hicks

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/2757753/rodney-j-hicks-publications-by-citations.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

475  
papers

20,881  
citations

72  
h-index

127  
g-index

509  
ext. papers

24,942  
ext. citations

5.8  
avg, IF

6.9  
L-index

#	Paper	IF	Citations
475	Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 571-8	2.2	1113
474	Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3048-58	2.2	927
473	[Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 825-833 <sup>21.7</sup>	21.7	545
472	Delivering affordable cancer care in high-income countries. <i>Lancet Oncology, The</i> , <b>2011</b> , 12, 933-80	21.7	476
471	Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. <i>Lancet, The</i> , <b>2020</b> , 395, 1208-1216	4.0	472
470	Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 2098-104	2.2	471
469	Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 1285-92	2.2	369
468	Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 2391-401	12.9	331
467	Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. <i>Radiographics</i> , <b>2015</b> , 35, 500-16	5.4	309
466	90Y-edotreotide for metastatic carcinoid refractory to octreotide. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1652-9	2.2	256
465	MRI-negative PET-positive temporal lobe epilepsy: a distinct surgically remediable syndrome. <i>Brain</i> , <b>2004</b> , 127, 2276-85	11.2	255
464	High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2001</b> , 50, 287-93	4	245
463	Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 1211-1223	59.2	226
462	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine & Hybrid Imaging. <i>Neuroendocrinology</i> , <b>2017</b> , 105, 212-244	5.6	196
461	UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. <i>Cancer Research</i> , <b>2015</b> , 75, 5228-34	10.1	196
460	F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment. <i>Cancer</i> , <b>2001</b> , 92, 886-95	6.4	195
459	Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer. <i>Head and Neck</i> , <b>2005</b> , 27, 175-81	4.2	193

458	Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. <i>Blood</i> , <b>2015</b> , 125, 3679-87	2.2	190
457	Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 111-8	2.2	188
456	High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. <i>Journal of Medical Imaging and Radiation Oncology</i> , <b>2012</b> , 56, 40-7	1.7	183
455	Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. <i>Cancer Discovery</i> , <b>2014</b> , 4, 423-33	24.4	180
454	Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1527-33	3.2	173
453	Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 535-42	2.2	170
452	Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls. <i>Radiographics</i> , <b>2018</b> , 38, 200-217	5.4	152
451	A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer. <i>Radiotherapy and Oncology</i> , <b>2006</b> , 78, 254-61	5.3	151
450	Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2004</b> , 60, 412-8	4	151
449	Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure. <i>Lung Cancer</i> , <b>2005</b> , 49, 95-108	5.9	145
448	An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. <i>Journal of Clinical Investigation</i> , <b>2012</b> , 122, 553-7	15.9	144
447	Dosimetry of Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes. <i>Journal of Nuclear Medicine</i> , <b>2019</b> , 60, 517-523	8.9	144
446	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues. <i>Neuroendocrinology</i> , <b>2017</b> , 105, 295-309	5.6	142
445	Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1628-34	2.2	141
444	Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. <i>American Journal of Medicine</i> , <b>2002</b> , 112, 262-8	2.4	138
443	EANM procedure guidelines for radionuclide therapy with Lu-labelled PSMA-ligands (Lu-PSMA-RLT). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2019</b> , 46, 2536-2544	8.8	136
442	FDG PET/CT for assessing tumour response to immunotherapy : Report on the EANM symposium on immune modulation and recent review of the literature. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2019</b> , 46, 238-250	8.8	130
441	Role of 18F-FDG PET in assessment of response in non-small cell lung cancer. <i>Journal of Nuclear Medicine</i> , <b>2009</b> , 50 Suppl 1, 31S-42S	8.9	121

440	Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2005</b> , 32, 1384-91	8.8	120
439	Clinical impact of, and prognostic stratification by, F-18 FDG PET/CT in head and neck mucosal squamous cell carcinoma. <i>Head and Neck</i> , <b>2007</b> , 29, 986-95	4.2	119
438	European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of pheochromocytoma and paraganglioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2019</b> , 46, 2112-2137	8.8	113
437	Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 3304-15	12.9	111
436	The impact of PET/CT in the management of recurrent ovarian cancer. <i>Gynecologic Oncology</i> , <b>2006</b> , 103, 271-6	4.9	110
435	The impact of PET-CT in suspected recurrent ovarian cancer: A prospective multi-centre study as part of the Australian PET Data Collection Project. <i>Gynecologic Oncology</i> , <b>2009</b> , 112, 462-8	4.9	109
434	Is there still a role for SPECT-CT in oncology in the PET-CT era?. <i>Nature Reviews Clinical Oncology</i> , <b>2012</b> , 9, 712-20	19.4	106
433	The clinical impact of (18)F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. <i>Journal of Nuclear Medicine</i> , <b>2002</b> , 43, 492-9	8.9	103
432	(68)Ga-DOTATATE and (18)F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity. <i>Cancer Imaging</i> , <b>2016</b> , 16, 22	5.6	102
431	Impact of [18F] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-hodgkin lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2008</b> , 71, 213-9	4	99
430	Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Nuclear Medicine</i> , <b>2020</b> , 61, 857-865	8.9	99
429	Can structural or functional changes following traumatic brain injury in the rat predict epileptic outcome?. <i>Epilepsia</i> , <b>2013</b> , 54, 1240-50	6.4	97
428	Findings on 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery. <i>Journal of Nuclear Medicine</i> , <b>2006</b> , 47, 14-22	8.9	97
427	Investigations with FDG-PET scanning in prostate cancer show limited value for clinical practice. <i>Acta Oncologica</i> , <b>2002</b> , 41, 425-9	3.2	96
426	The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer. <i>British Journal of Cancer</i> , <b>2009</b> , 100, 693-700	8.7	93
425	Quantitative (177)Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system. <i>Cancer Imaging</i> , <b>2011</b> , 11, 56-66	5.6	92
424	Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2017</b> , 102, 3278-3287	5.6	91
423	The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2012</b> , 39, 50-6	8.8	90

4 <sup>22</sup>	Does positron emission tomography change management in primary rectal cancer? A prospective assessment. <i>Diseases of the Colon and Rectum</i> , <b>2004</b> , 47, 451-8	3.1	88
4 <sup>21</sup>	Improving diagnosis of tumor-induced osteomalacia with Gallium-68 DOTATATE PET/CT. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2013</b> , 98, 687-94	5.6	87
4 <sup>20</sup>	The extent of resection of FDG-PET hypometabolism relates to outcome of temporal lobectomy. <i>Brain</i> , <b>2007</b> , 130, 548-60	11.2	86
4 <sup>19</sup>	The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2017</b> , 44, 67-77	8.8	84
4 <sup>18</sup>	Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2009</b> , 75, 1098-104	4	84
4 <sup>17</sup>	Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA--first small animal PET results. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , <b>2007</b> , 10, 203-11	3.4	84
4 <sup>16</sup>	18F-FDG PET/CT has a high impact on patient management and provides powerful prognostic stratification in the primary staging of esophageal cancer: a prospective study with mature survival data. <i>Journal of Nuclear Medicine</i> , <b>2012</b> , 53, 864-71	8.9	82
4 <sup>15</sup>	Impact of positron emission tomography on the management of patients with small-cell lung cancer: preliminary experience. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2004</b> , 27, 164-71	2.7	79
4 <sup>14</sup>	Initial Experience With Gallium-68 DOTA-Octreotate PET/CT and Peptide Receptor Radionuclide Therapy for Pediatric Patients With Refractory Metastatic Neuroblastoma. <i>Journal of Pediatric Hematology/Oncology</i> , <b>2016</b> , 38, 87-96	1.2	79
4 <sup>13</sup>	FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 1733-1742	8.9	79
4 <sup>12</sup>	Cancer Imaging reviewer acknowledgement 2015. <i>Cancer Imaging</i> , <b>2016</b> , 16,	5.6	78
4 <sup>11</sup>	Powerful prognostic stratification by [18F]fluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer treated with high-dose chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 3026-31	2.2	76
4 <sup>10</sup>	Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for Lu-labelled PSMA Radioligand Therapy. <i>European Urology Oncology</i> , <b>2019</b> , 2, 670-676	6.7	74
4 <sup>09</sup>	Gastrointestinal neuroendocrine (carcinoid) tumours: current diagnosis and management. <i>Medical Journal of Australia</i> , <b>2010</b> , 193, 46-52	4	74
4 <sup>08</sup>	Hypometabolism precedes limbic atrophy and spontaneous recurrent seizures in a rat model of TLE. <i>Epilepsia</i> , <b>2012</b> , 53, 1233-44	6.4	73
4 <sup>07</sup>	68Ga PET/CT ventilation-perfusion imaging for pulmonary embolism: a pilot study with comparison to conventional scintigraphy. <i>Journal of Nuclear Medicine</i> , <b>2011</b> , 52, 1513-9	8.9	73
4 <sup>06</sup>	Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 4418-25	2.2	72
4 <sup>05</sup>	An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development. <i>Cancer Research</i> , <b>2005</b> , 65, 9633-6	10.1	72

404	Quantitative evaluation of regional substrate metabolism in the human heart by positron emission tomography. <i>Journal of the American College of Cardiology</i> , <b>1991</b> , 18, 101-11	15.1	72
403	Depression in temporal lobe epilepsy surgery patients: an FDG-PET study. <i>Epilepsia</i> , <b>2006</b> , 47, 2125-30	6.4	70
402	PET imaging of tumours with a <sup>64</sup> Cu labeled macrobicyclic cage amine ligand tethered to Tyr3-octreotate. <i>Dalton Transactions</i> , <b>2014</b> , 43, 1386-96	4.3	69
401	Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2015</b> , 42, 176-85	8.8	68
400	Harmonizing FDG PET quantification while maintaining optimal lesion detection: prospective multicentre validation in 517 oncology patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2015</b> , 42, 2072-82	8.8	68
399	Abscopal [corrected] effects after conventional and stereotactic lung irradiation of non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2013</b> , 8, e71-2	8.9	68
398	Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma. <i>Clinical Lymphoma and Myeloma</i> , <b>2003</b> , 4, 43-9		68
397	A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol. <i>BJU International</i> , <b>2018</b> , 122, 763-793	5.6	67
396	Initial staging of lymphoma with positron emission tomography and computed tomography. <i>Seminars in Nuclear Medicine</i> , <b>2005</b> , 35, 165-75	5.4	67
395	In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras(G12D);Pten deletion mouse model of ovarian cancer. <i>Molecular Cancer Therapeutics</i> , <b>2011</b> , 10, 1440-9	6.1	66
394	Overview of early response assessment in lymphoma with FDG-PET. <i>Cancer Imaging</i> , <b>2007</b> , 7, 10-8	5.6	66
393	Early mortality after radical radiotherapy for non-small-cell lung cancer: comparison of PET-staged and conventionally staged cohorts treated at a large tertiary referral center. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2002</b> , 52, 351-61	4	66
392	Regulation of rDNA transcription in response to growth factors, nutrients and energy. <i>Gene</i> , <b>2015</b> , 556, 27-34	3.8	65
391	<sup>18</sup> F-FDG PET provides high-impact and powerful prognostic stratification in the staging of Merkel cell carcinoma: a 15-year institutional experience. <i>Journal of Nuclear Medicine</i> , <b>2013</b> , 54, 1223-9	8.9	65
390	Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors. <i>European Journal of Cancer</i> , <b>2013</b> , 49, 3936-44	7.5	63
389	Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2018</b> , 45, 262-277	8.8	62
388	Validating and improving CT ventilation imaging by correlating with ventilation 4D-PET/CT using <sup>68</sup> Ga-labeled nanoparticles. <i>Medical Physics</i> , <b>2014</b> , 41, 011910	4.4	62
387	Patterns of failure and prognostic factor analyses in locally advanced cervical cancer patients staged by positron emission tomography and treated with curative intent. <i>International Journal of Gynecological Cancer</i> , <b>2009</b> , 19, 912-8	3.5	62



386	Usefulness of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with a residual structural abnormality after definitive treatment for squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , <b>2004</b> , 26, 1008-17	4.2	62
385	The usefulness of fluorine 18-labelled deoxyglucose positron emission tomography in the investigation of patients with cervical lymphadenopathy from an unknown primary tumor. <i>Head and Neck</i> , <b>2003</b> , 25, 138-45	4.2	62
384	Effect of PET/CT on management of patients with non-small cell lung cancer: results of a prospective study with 5-year survival data. <i>Journal of Nuclear Medicine</i> , <b>2012</b> , 53, 1007-15	8.9	61
383	High rates of tumor growth and disease progression detected on serial pretreatment fluorodeoxyglucose-positron emission tomography/computed tomography scans in radical radiotherapy candidates with nonsmall cell lung cancer. <i>Cancer</i> , <b>2010</b> , 116, 5030-7	6.4	61
382	Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2014</b> , 41, 1831-44	8.8	60
381	Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer. <i>Journal of Nuclear Medicine</i> , <b>2014</b> , 55, 1069-74	8.9	60
380	Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2017</b> , 44, 1622-1635	8.8	59
379	A desferrioxamine B squaramide ester for the incorporation of zirconium-89 into antibodies. <i>Chemical Communications</i> , <b>2016</b> , 52, 11889-11892	5.8	59
378	Progressive metabolic and structural cerebral perturbations after traumatic brain injury: an in vivo imaging study in the rat. <i>Journal of Nuclear Medicine</i> , <b>2010</b> , 51, 1788-95	8.9	59
377	Comparative PET study using F-18 FET and F-18 FDG for the evaluation of patients with suspected brain tumour. <i>Journal of Clinical Neuroscience</i> , <b>2010</b> , 17, 43-9	2.2	59
376	The cost-effective use of 18F-FDG PET in the presurgical evaluation of medically refractory focal epilepsy. <i>Journal of Nuclear Medicine</i> , <b>2008</b> , 49, 931-7	8.9	59
375	Consensus on molecular imaging and theranostics in prostate cancer. <i>Lancet Oncology</i> , <b>2018</b> , 19, e696-e708	21.7	59
374	High-resolution pulmonary ventilation and perfusion PET/CT allows for functionally adapted intensity modulated radiotherapy in lung cancer. <i>Radiotherapy and Oncology</i> , <b>2015</b> , 115, 157-62	5.3	57
373	Significant clinical impact and prognostic stratification provided by FDG-PET in the staging of oesophageal cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2006</b> , 33, 759-69	8.8	57
372	Cu-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy. <i>Journal of Nuclear Medicine</i> , <b>2019</b> , 60, 777-785	8.9	57
371	Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma. <i>Melanoma Research</i> , <b>2014</b> , 24, 504-8	3.3	56
370	How do oncologists deal with incidental abnormalities on whole-body fluorine-18 fluorodeoxyglucose PET/CT?. <i>Cancer</i> , <b>2007</b> , 109, 117-24	6.4	56
369	Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study. <i>Lancet Haematology</i> , <b>2015</b> , 2, e445-55	14.6	54

368	Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy. <i>Cancer Imaging</i> , <b>2010</b> , 10 Spec no A, S83-91	5.6	54
367	<sup>18</sup> F-FDG PET response to neoadjuvant chemotherapy for Ewing sarcoma and osteosarcoma are different. <i>Skeletal Radiology</i> , <b>2011</b> , 40, 1007-15	2.7	53
366	Reproducibility of "intelligent" contouring of gross tumor volume in non-small-cell lung cancer on PET/CT images using a standardized visual method. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2010</b> , 77, 1151-7	4	53
365	An automated voxelized dosimetry tool for radionuclide therapy based on serial quantitative SPECT/CT imaging. <i>Medical Physics</i> , <b>2013</b> , 40, 112503	4.4	52
364	Pilot comparison of F-fluorocholine and F-fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , <b>2010</b> , 54, 325-32	1.7	52
363	Impact of <sup>18</sup> F-fluorodeoxyglucose positron emission tomography before and after definitive radiation therapy in patients with apparently solitary plasmacytoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2009</b> , 74, 740-6	4	52
362	The genomic landscape of pheochromocytoma. <i>Journal of Pathology</i> , <b>2015</b> , 236, 78-89	9.4	51
361	Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [ <sup>177</sup> Lu]-PSMA-617. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2020</b> , 47, 2322-2327	8.8	51
360	Deep Learning Renal Segmentation for Fully Automated Radiation Dose Estimation in Unsealed Source Therapy. <i>Frontiers in Oncology</i> , <b>2018</b> , 8, 215	5.3	51
359	Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of Ga-Tris(Hydroxypyridinone)-PSMA PET/CT in Patients with Prostate Cancer. <i>Journal of Nuclear Medicine</i> , <b>2018</b> , 59, 625-631	8.9	50
358	<sup>177</sup> Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity <sup>111</sup> In-octreotide. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2010</b> , 37, 1869-75	8.8	50
357	FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2006</b> , 33, 770-8	8.8	49
356	Imaging of hypoxia with <sup>18</sup> F-FAZA PET in patients with locally advanced non-small cell lung cancer treated with definitive chemoradiotherapy. <i>Journal of Medical Imaging and Radiation Oncology</i> , <b>2013</b> , 57, 475-81	1.7	48
355	Impact of post-therapy positron emission tomography on prognostic stratification and surveillance after chemoradiotherapy for cervical cancer. <i>Cancer</i> , <b>2011</b> , 117, 3981-8	6.4	48
354	Changing paradigms with molecular imaging of neuroendocrine tumors. <i>Discovery Medicine</i> , <b>2012</b> , 14, 71-81	2.5	48
353	New Tris(hydroxypyridinone) Bifunctional Chelators Containing Isothiocyanate Groups Provide a Versatile Platform for Rapid One-Step Labeling and PET Imaging with ( <sup>68</sup> Ga(3+)). <i>Bioconjugate Chemistry</i> , <b>2016</b> , 27, 309-18	6.3	47
352	High-contrast PET of melanoma using ( <sup>18</sup> F)-MEL050, a selective probe for melanin with predominantly renal clearance. <i>Journal of Nuclear Medicine</i> , <b>2010</b> , 51, 441-7	8.9	47
351	Impact of point spread function reconstruction on thoracic lymph node staging with <sup>18</sup> F-FDG PET/CT in non-small cell lung cancer. <i>Clinical Nuclear Medicine</i> , <b>2012</b> , 37, 971-6	1.7	47



350	How We Read Oncologic FDG PET/CT. <i>Cancer Imaging</i> , <b>2016</b> , 16, 35	5.6	46
349	The use of fused PET/CT images for patient selection and radical radiotherapy target volume definition in patients with non-small cell lung cancer: results of a prospective study with mature survival data. <i>Radiotherapy and Oncology</i> , <b>2013</b> , 106, 292-8	5.3	46
348	Gallium-68 complex of a macrobicyclic cage amine chelator tethered to two integrin-targeting peptides for diagnostic tumor imaging. <i>Bioconjugate Chemistry</i> , <b>2011</b> , 22, 2093-103	6.3	46
347	<sup>18</sup> F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model. <i>Journal of Nuclear Medicine</i> , <b>2010</b> , 51, 1559-64	8.9	46
346	Prognostic and predictive significance of plasma HGF and IL-8 in a phase III trial of chemoradiation with or without tirapazamine in locoregionally advanced head and neck cancer. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 1798-807	12.9	46
345	Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging. <i>Molecular Cancer Therapeutics</i> , <b>2005</b> , 4, 1417-22	6.1	46
344	<sup>18</sup> F-flumazenil: a $\beta$ -aminobutyric acid A-specific PET radiotracer for the localization of drug-resistant temporal lobe epilepsy. <i>Journal of Nuclear Medicine</i> , <b>2013</b> , 54, 1270-7	8.9	45
343	Association between pulmonary uptake of fluorodeoxyglucose detected by positron emission tomography scanning after radiation therapy for non-small-cell lung cancer and radiation pneumonitis. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2011</b> , 80, 1365-71	4	45
342	Discovery of [ <sup>18</sup> F]N-(2-(diethylamino)ethyl)-6-fluoronicotinamide: a melanoma positron emission tomography imaging radiotracer with high tumor to body contrast ratio and rapid renal clearance. <i>Journal of Medicinal Chemistry</i> , <b>2009</b> , 52, 5299-302	8.3	45
341	Management of the neck after chemoradiotherapy for head and neck cancers in Asia: consensus statement from the Asian Oncology Summit 2009. <i>Lancet Oncology</i> , <b>2009</b> , 10, 1086-92	21.7	45
340	Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. <i>Anti-Cancer Drugs</i> , <b>2008</b> , 19, 547-52	2.4	42
339	Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance. <i>International Journal of Cancer</i> , <b>2018</b> , 142, 2139-2152	7.5	41
338	Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14. <i>Haematologica</i> , <b>2017</b> , 102, 356-363	6.6	40
337	The impact of time between staging PET/CT and definitive chemo-radiation on target volumes and survival in patients with non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , <b>2013</b> , 106, 288-91	5.3	40
336	Pretreatment transcriptional profiling for predicting response to neoadjuvant chemoradiotherapy in rectal adenocarcinoma. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 3039-47	12.9	40
335	The role of PET in monitoring therapy. <i>Cancer Imaging</i> , <b>2005</b> , 5, 51-7	5.6	39
334	The effects of afterload reduction on myocardial carbon 11-labeled acetate kinetics and noninvasively estimated mechanical efficiency in patients with dilated cardiomyopathy. <i>Journal of Nuclear Cardiology</i> , <b>1994</b> , 1, 3-16	2.1	39
333	A Phase IIa Randomized Control Trial of $\text{Na}_2\text{SeO}_3$ (Sodium Selenate) in Mild-Moderate Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , <b>2016</b> , 54, 223-32	4.3	38

332	High-administered activity In-111 octreotide therapy with concomitant radiosensitizing 5FU chemotherapy for treatment of neuroendocrine tumors: preliminary experience. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , <b>2009</b> , 24, 527-33	3.9	37
331	The use of positron emission tomography (PET) in the staging/evaluation, treatment, and follow-up of patients with lung cancer: a critical review. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2008</b> , 72, 1298-306	4	37
330	FDG-PET-detected extracranial metastasis in patients with non-small cell lung cancer undergoing staging for surgery or radical radiotherapy--survival correlates with metastatic disease burden. <i>Acta Oncologica</i> , <b>2003</b> , 42, 48-54	3.2	37
329	Prediction of outcome after revascularization in patients with poor left ventricular function. <i>Annals of Thoracic Surgery</i> , <b>1996</b> , 61, 1428-34	2.7	37
328	Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. <i>European Journal of Cancer</i> , <b>2018</b> , 105, 88-102	7.5	37
327	Analysis of <sup>177</sup> Lu-DOTA-octreotate therapy-induced DNA damage in peripheral blood lymphocytes of patients with neuroendocrine tumors. <i>Journal of Nuclear Medicine</i> , <b>2015</b> , 56, 505-11	8.9	36
326	High clinical and morphologic response using Y-DOTA-octreotate sequenced with Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2017</b> , 44, 476-489	8.8	36
325	Multi-tracer small animal PET imaging of the tumour response to the novel pan-Erb-B inhibitor CI-1033. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2006</b> , 33, 441-52	8.8	36
324	Clinical applications of molecular imaging in sarcoma evaluation. <i>Cancer Imaging</i> , <b>2005</b> , 5, 66-72	5.6	36
323	Rapid kit-based ( <sup>68</sup> Ga)-labelling and PET imaging with THP-Tyr(3)-octreotate: a preliminary comparison with DOTA-Tyr(3)-octreotate. <i>EJNMMI Research</i> , <b>2015</b> , 5, 52	3.6	35
322	structural rearrangements in metastatic pheochromocytomas. <i>Endocrine-Related Cancer</i> , <b>2018</b> , 25, 1-9	5.7	35
321	Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 5873-5882	12.9	35
320	The role of positron emission tomography/computed tomography in radiation therapy planning for patients with lung cancer. <i>Seminars in Nuclear Medicine</i> , <b>2012</b> , 42, 308-19	5.4	35
319	[ <sup>18</sup> F]fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma. <i>Clinical Lymphoma and Myeloma</i> , <b>2008</b> , 8, 159-65		35
318	'MRI-negative PET-positive' temporal lobe epilepsy (TLE) and mesial TLE differ with quantitative MRI and PET: a case control study. <i>BMC Neurology</i> , <b>2007</b> , 7, 16	3.1	35
317	PET/CT: will it change the way that we use CT in cancer imaging?. <i>Cancer Imaging</i> , <b>2006</b> , 6, S52-62	5.6	35
316	High-resolution imaging of pulmonary ventilation and perfusion with <sup>68</sup> Ga-VQ respiratory gated (4-D) PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2014</b> , 41, 343-9	8.8	34
315	In vivo tracking of dendritic cells in patients with multiple myeloma. <i>Journal of Immunotherapy</i> , <b>2008</b> , 31, 166-79	5	34

314	PET scanning in lung cancer: current status and future directions. <i>Journal of Surgical Oncology</i> , <b>2003</b> , 21, 149-55		34
313	Supranutritional Sodium Selenate Supplementation Delivers Selenium to the Central Nervous System: Results from a Randomized Controlled Pilot Trial in Alzheimer's Disease. <i>Neurotherapeutics</i> , <b>2019</b> , 16, 192-202	6.4	34
312	Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. <i>European Journal of Cancer</i> , <b>2021</b> , 146, 56-73	7.5	32
311	Myeloid neoplasms after chemotherapy and PRRT: myth and reality. <i>Endocrine-Related Cancer</i> , <b>2016</b> , 23, C1-7	5.7	31
310	Hypoxia in head and neck cancer: studies with hypoxic positron emission tomography imaging and hypoxic cytotoxins. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2007</b> , 69, S61-3	4	31
309	Improving patient selection for 18F-FDG PET scanning in the staging of gastric cancer. <i>Journal of Nuclear Medicine</i> , <b>2015</b> , 56, 523-9	8.9	30
308	Ventilation/Perfusion Positron Emission Tomography--Based Assessment of Radiation Injury to Lung. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2015</b> , 93, 408-17	4	30
307	Validation of a 4D-PET maximum intensity projection for delineation of an internal target volume. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2013</b> , 86, 749-54	4	29
306	Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: results of a multicentre prospective study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2009</b> , 36, 347-53	8.8	29
305	Radiation changes do not interfere with postchemoradiation restaging of patients with rectal cancer by FDG PET/CT before curative surgical therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2009</b> , 74, 60-6	4	29
304	Functional imaging techniques for evaluation of sarcomas. <i>Cancer Imaging</i> , <b>2005</b> , 5, 58-65	5.6	29
303	FAPI PET/CT: Will It End the Hegemony of F-FDG in Oncology?. <i>Journal of Nuclear Medicine</i> , <b>2021</b> , 62, 296-302	8.9	29
302	Bayesian approach to determining penetrance of pathogenic SDH variants. <i>Journal of Medical Genetics</i> , <b>2018</b> , 55, 729-734	5.8	29
301	Correlation of p16 status, hypoxic imaging using [18F]-misonidazole positron emission tomography and outcome in patients with loco-regionally advanced head and neck cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , <b>2014</b> , 58, 89-97	1.7	28
300	Improved detection of regional melanoma metastasis using 18F-6-fluoro-N-[2-(diethylamino)ethyl]pyridine-3-carboxamide, a melanin-specific PET probe, by perilesional administration. <i>Journal of Nuclear Medicine</i> , <b>2011</b> , 52, 115-22	8.9	28
299	Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models. <i>Journal of Nuclear Medicine</i> , <b>2011</b> , 52, 1261-7	8.9	28
298	18F-FDG PET as a surrogate biomarker in non-small cell lung cancer treated with erlotinib: newly identified lesions are more informative than standardized uptake value. <i>Journal of Nuclear Medicine</i> , <b>2012</b> , 53, 530-7	8.9	28
297	High throughput static and dynamic small animal imaging using clinical PET/CT: potential preclinical applications. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2010</b> , 37, 991-1001	8.8	28

296	Impact of complementary parathyroid scintigraphy and ultrasonography on the surgical management of hyperparathyroidism. <i>Surgery</i> , <b>1996</b> , 120, 845-51	3.6	28
295	Changes in biodistribution on Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression. <i>Cancer Imaging</i> , <b>2018</b> , 18, 3	5.6	27
294	The utility of 18 F-FDG PET/CT for suspected recurrent breast cancer: impact and prognostic stratification. <i>Cancer Imaging</i> , <b>2014</b> , 14, 13	5.6	27
293	Rapid blood clearance and lack of long-term renal toxicity of 177Lu-DOTATATE enables shortening of renoprotective amino acid infusion. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2013</b> , 40, 1853-60	8.8	27
292	PET for sarcomas other than gastrointestinal stromal tumors. <i>Oncologist</i> , <b>2008</b> , 13 Suppl 2, 22-6	5.7	27
291	Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2019</b> , 46, 1902-1910	8.8	26
290	Pulmonary Scintigraphy for the Diagnosis of Acute Pulmonary Embolism: A Survey of Current Practices in Australia, Canada, and France. <i>Journal of Nuclear Medicine</i> , <b>2015</b> , 56, 1212-7	8.9	26
289	Does PET SUV Harmonization Affect PERCIST Response Classification?. <i>Journal of Nuclear Medicine</i> , <b>2016</b> , 57, 1699-1706	8.9	26
288	Ga-68 MAA Perfusion 4D-PET/CT Scanning Allows for Functional Lung Avoidance Using Conformal Radiation Therapy Planning. <i>Technology in Cancer Research and Treatment</i> , <b>2016</b> , 15, 114-21	2.7	26
287	Pheo-Type: A Diagnostic Gene-expression Assay for the Classification of Pheochromocytoma and Paraganglioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2016</b> , 101, 1034-43	5.6	26
286	Geographic miss of lung tumours due to respiratory motion: a comparison of 3D vs 4D PET/CT defined target volumes. <i>Radiation Oncology</i> , <b>2014</b> , 9, 291	4.2	26
285	Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2011</b> , 38, 642-50	8.8	26
284	Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic Melanoma.. <i>JCO Precision Oncology</i> , <b>2017</b> , 1, 1-14	3.6	25
283	Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol. <i>Thyroid</i> , <b>2019</b> , 29, 1634-1645	6.2	25
282	68Ga-EDTA PET/CT imaging and plasma clearance for glomerular filtration rate quantification: comparison to conventional 51Cr-EDTA. <i>Journal of Nuclear Medicine</i> , <b>2015</b> , 56, 405-9	8.9	25
281	Phase 1 study of tirapazamine in combination with radiation and weekly cisplatin in patients with locally advanced cervical cancer. <i>International Journal of Gynecological Cancer</i> , <b>2010</b> , 20, 827-33	3.5	25
280	PET/CT Lung Ventilation and Perfusion Scanning using Galligas and Gallium-68-MAA. <i>Seminars in Nuclear Medicine</i> , <b>2019</b> , 49, 71-81	5.4	25
279	Enhancing PET Signal at Target Tissue in Vivo: Dendritic and Multimeric Tris(hydroxypyridinone) Conjugates for Molecular Imaging of Integrin Expression with Gallium-68. <i>Bioconjugate Chemistry</i> , <b>2017</b> , 28, 481-495	6.3	24

278	Intra-individual comparison of Ga-PSMA-11 and F-DCFPyL normal-organ biodistribution. <i>Cancer Imaging</i> , <b>2019</b> , 19, 23	5.6	24
277	Distribution Atlas of Proliferating Bone Marrow in Non-Small Cell Lung Cancer Patients Measured by FLT-PET/CT Imaging, With Potential Applicability in Radiation Therapy Planning. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2015</b> , 92, 1035-1043	4	24
276	F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma. <i>Cancer Imaging</i> , <b>2020</b> , 20, 36	5.6	24
275	Use of FDG PET/CT for investigation of febrile neutropenia: evaluation in high-risk cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2012</b> , 39, 1348-55	8.8	24
274	Imaging in the diagnosis and treatment of non-small cell lung cancer. <i>Respirology</i> , <b>2007</b> , 12, 165-72	3.6	24
273	Early therapeutic response assessment by (18)FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure. <i>Leukemia and Lymphoma</i> , <b>2007</b> , 48, 596-600	1.9	24
272	Molecular imaging in the investigation of hypoglycaemic syndromes and their management. <i>Endocrine-Related Cancer</i> , <b>2017</b> , 24, R203-R221	5.7	23
271	F-FDG-Avid Thyroid Incidentalomas: The Importance of Contextual Interpretation. <i>Journal of Nuclear Medicine</i> , <b>2018</b> , 59, 749-755	8.9	23
270	A phase II study of induction carboplatin and gemcitabine followed by chemoradiotherapy for the treatment of locally advanced nasopharyngeal carcinoma. <i>Oral Oncology</i> , <b>2013</b> , 49, 468-74	4.4	23
269	Prospective Study of Serial Imaging Comparing Fluorodeoxyglucose Positron Emission Tomography (PET) and Fluorothymidine PET During Radical Chemoradiation for Non-Small Cell Lung Cancer: Reduction of Detectable Proliferation Associated With Worse Survival. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2017</b> , 99, 947-955	4	23
268	Evaluation of high-risk melanoma: comparison of [18F]FDG PET and high-dose 67Ga SPET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2002</b> , 29, 506-15	8.8	23
267	Detection of Synchronous Primary Malignancies with Ga-Labeled Prostate-Specific Membrane Antigen PET/CT in Patients with Prostate Cancer: Frequency in 764 Patients. <i>Journal of Nuclear Medicine</i> , <b>2017</b> , 58, 1938-1942	8.9	22
266	Bifunctional (64)Cu-labelled macrobicyclic cage amine isothiocyanates for immuno-positron emission tomography. <i>Dalton Transactions</i> , <b>2015</b> , 44, 4901-9	4.3	22
265	Effect of Platinum-Based Chemoradiotherapy on Cellular Proliferation in Bone Marrow and Spleen, Estimated by (18)F-FLT PET/CT in Patients with Locally Advanced Non-Small Cell Lung Cancer. <i>Journal of Nuclear Medicine</i> , <b>2014</b> , 55, 1075-80	8.9	22
264	A prospective observational study of Gallium-68 ventilation and perfusion PET/CT during and after radiotherapy in patients with non-small cell lung cancer. <i>BMC Cancer</i> , <b>2014</b> , 14, 740	4.8	22
263	CAPTEM in Metastatic Well-Differentiated Intermediate to High Grade Neuroendocrine Tumors: A Single Centre Experience. <i>Journal of Oncology</i> , <b>2019</b> , 2019, 9032753	4.5	21
262	15-Year Experience of 18F-FDG PET Imaging in Response Assessment and Restaging After Definitive Treatment of Merkel Cell Carcinoma. <i>Journal of Nuclear Medicine</i> , <b>2015</b> , 56, 1328-33	8.9	21
261	The value of positron emission tomography in prognosis and response assessment in non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , <b>2010</b> , 51 Suppl 1, 28-33	1.9	21



260	Radiosynthesis and biological evaluation of L- and D-S-(3-[18F]fluoropropyl)homocysteine for tumor imaging using positron emission tomography. <i>Journal of Medicinal Chemistry</i> , <b>2011</b> , 54, 1860-70	8.3	21
259	Radiation Dosimetry in Lu-PSMA-617 Therapy Using a Single Posttreatment SPECT/CT Scan: A Novel Methodology to Generate Time- and Tissue-Specific Dose Factors. <i>Journal of Nuclear Medicine</i> , <b>2020</b> , 61, 1030-1036	8.9	21
258	Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH-MYCN neuroblastoma mouse model. <i>International Journal of Cancer</i> , <b>2016</b> , 139, 194-204 <sup>5</sup>	7.5	21
257	Correlation of 68Ga Ventilation-Perfusion PET/CT with Pulmonary Function Test Indices for Assessing Lung Function. <i>Journal of Nuclear Medicine</i> , <b>2015</b> , 56, 1718-23	8.9	20
256	FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2020</b> , 47, 2776-2786	8.8	20
255	Quantitative and qualitative analysis of [(18)F]FDG and [(18)F]FAZA positron emission tomography of head and neck cancers and associations with HPV status and treatment outcome. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2016</b> , 43, 617-25	8.8	20
254	Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 1: The Role of F-FDG PET/CT. <i>Journal of Nuclear Medicine</i> , <b>2020</b> , 61, 943-950	8.9	20
253	Gallium-68 EDTA PET/CT for Renal Imaging. <i>Seminars in Nuclear Medicine</i> , <b>2016</b> , 46, 448-61	5.4	19
252	Pertuzumab and erlotinib in patients with relapsed non-small cell lung cancer: a phase II study using 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging. <i>Oncologist</i> , <b>2014</b> , 19, 175-6	5.7	19
251	In-vivo imaging characteristics of two fluorinated flumazenil radiotracers in the rat. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2009</b> , 36, 958-65	8.8	19
250	Atypical brown fat distribution in young males demonstrated on PET/CT. <i>Clinical Nuclear Medicine</i> , <b>2007</b> , 32, 679-82	1.7	19
249	Enteropathy-associated T-cell lymphoma without a prior diagnosis of coeliac disease: diagnostic dilemmas and management options. <i>Annals of Hematology</i> , <b>2005</b> , 84, 118-21	3	19
248	Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments. <i>European Urology Oncology</i> , <b>2019</b> , 2, 152-162	6.7	19
247	Peptide Receptor Radiotherapy: Current Approaches and Future Directions. <i>Current Treatment Options in Oncology</i> , <b>2019</b> , 20, 77	5.4	18
246	Moving Beyond "Lumpology": PET/CT Imaging of Pheochromocytoma and Paraganglioma. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 3815-7	12.9	18
245	Enhancing the anti-tumour activity of Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP. <i>Scientific Reports</i> , <b>2020</b> , 10, 10196	4.9	18
244	Impact of fluorine-18 fluorodeoxyglucose positron emission tomography on diagnosis and antimicrobial utilization in patients with high-risk febrile neutropenia. <i>Leukemia and Lymphoma</i> , <b>2012</b> , 53, 1889-95	1.9	18
243	PET imaging for suspected residual tumour or thoracic recurrence of non-small cell lung cancer after pneumonectomy. <i>Lung Cancer</i> , <b>2005</b> , 47, 49-57	5.9	18



242	The utility of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in the investigation of patients with disseminated carcinoma of unknown primary origin. <i>Molecular Imaging and Biology</i> , <b>2005</b> , 7, 236-43	3.8	18
241	Use of carbon-11 acetate and dynamic positron emission tomography to assess regional myocardial oxygen consumption in patients with acute myocardial infarction receiving thrombolysis or coronary angioplasty. <i>American Journal of Cardiology</i> , <b>1993</b> , 71, 529-35	3	18
240	<sup>18</sup> F-FDG PET/CT following chemoradiation of uterine cervix cancer provides powerful prognostic stratification independent of HPV status: a prospective cohort of 105 women with mature survival data. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2015</b> , 42, 1825-32	8.8	17
239	Gallium-68 perfusion positron emission tomography/computed tomography to assess pulmonary function in lung cancer patients undergoing surgery. <i>Cancer Imaging</i> , <b>2016</b> , 16, 24	5.6	17
238	In vivo measurement of hippocampal GABAA/cBZR density with [18F]-flumazenil PET for the study of disease progression in an animal model of temporal lobe epilepsy. <i>PLoS ONE</i> , <b>2014</b> , 9, e86722	3.7	17
237	PET/MRI: a different spin from under the rim. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2009</b> , 36 Suppl 1, S10-4	8.8	17
236	The clinical significance and management of lesion motion due to respiration during PET/CT scanning. <i>Cancer Imaging</i> , <b>2011</b> , 11, 224-36	5.6	17
235	<sup>18</sup> F-FDG PET in candidates for radiation therapy: is it important and how do we validate its impact?. <i>Journal of Nuclear Medicine</i> , <b>2003</b> , 44, 30-2	8.9	17
234	Accuracy and Utility of Deformable Image Registration in (68)Ga 4D PET/CT Assessment of Pulmonary Perfusion Changes During and After Lung Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2015</b> , 93, 196-204	4	16
233	A Bivalent Inhibitor of Prostate Specific Membrane Antigen Radiolabeled with Copper-64 with High Tumor Uptake and Retention. <i>Angewandte Chemie - International Edition</i> , <b>2019</b> , 58, 14991-14994	16.4	16
232	Treatment response in the neck: p16+ versus p16- oropharyngeal cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , <b>2013</b> , 57, 364-72	1.7	16
231	Doing more harm than good? Do systematic reviews of PET by health technology assessment agencies provide an appraisal of the evidence that is closer to the truth than the primary data supporting its use?. <i>Journal of Nuclear Medicine</i> , <b>2011</b> , 52 Suppl 2, 64S-73S	8.9	16
230	The role of PET-CT in the management of patients with advanced cancer of the head and neck. <i>Current Oncology Reports</i> , <b>2008</b> , 10, 149-55	6.3	16
229	Applications of positron emission tomography in the development of molecular targeted cancer therapeutics. <i>BioDrugs</i> , <b>2003</b> , 17, 339-54	7.9	16
228	Positron emission tomography in pulmonary masses where tissue diagnosis is unhelpful or not possible. <i>Medical Journal of Australia</i> , <b>2001</b> , 175, 303-7	4	16
227	Recent developments in radiolabelled peptides for PET imaging of cancer. <i>Tetrahedron Letters</i> , <b>2016</b> , 57, 4119-4127	2	16
226	Metabolic patterns and seizure outcomes following anterior temporal lobectomy. <i>Annals of Neurology</i> , <b>2019</b> , 85, 241-250	9.4	16
225	Peptide Receptor Radionuclide Therapy with Cu-CuSarTATE Is Highly Efficacious Against a Somatostatin-Positive Neuroendocrine Tumor Model. <i>Journal of Nuclear Medicine</i> , <b>2020</b> , 61, 1800-1805	8.9	15

224	Postchemotherapy and tumor-selective targeting with the La-specific DAB4 monoclonal antibody relates to apoptotic cell clearance. <i>Journal of Nuclear Medicine</i> , <b>2014</b> , 55, 772-9	8.9	15
223	Absence of a relationship between tumor $^{18}$ F-fluorodeoxyglucose standardized uptake value and survival in patients treated with definitive radiotherapy for non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2014</b> , 9, 377-82	8.9	15
222	The role of thallium-201 and pentavalent dimercaptosuccinic acid for staging cartilaginous tumours. <i>International Seminars in Surgical Oncology</i> , <b>2004</b> , 1, 10		15
221	Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study. <i>Blood</i> , <b>2019</b> , 134, 756-756	2.2	15
220	Spleen Volume Variation in Patients with Locally Advanced Non-Small Cell Lung Cancer Receiving Platinum-Based Chemo-Radiotherapy. <i>PLoS ONE</i> , <b>2015</b> , 10, e0142608	3.7	15
219	The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review. <i>Oncologist</i> , <b>2017</b> , 22, 272-285	5.7	14
218	Peptide receptor chemoradionuclide therapy in small cell carcinoma: from bench to bedside. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2015</b> , 42, 25-32	8.8	14
217	Automatic delineation of functional lung volumes with Ga-ventilation/perfusion PET/CT. <i>EJNMMI Research</i> , <b>2017</b> , 7, 82	3.6	14
216	Ga PSMA-11 PET with CT urography protocol in the initial staging and biochemical relapse of prostate cancer. <i>Cancer Imaging</i> , <b>2017</b> , 17, 31	5.6	14
215	A prospective investigation into the clinical impact of 4D-PET/CT in the characterisation of solitary pulmonary nodules. <i>Cancer Imaging</i> , <b>2014</b> , 14, 24	5.6	14
214	High FDG activity in focal fat necrosis: a pitfall in interpretation of posttreatment PET/CT in patients with non-Hodgkin lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2013</b> , 40, 1330-6	8.8	14
213	Vacuum immobilisation reduces tumour excursion and minimises intrafraction error in a cohort study of stereotactic ablative body radiotherapy for pulmonary metastases. <i>Journal of Medical Imaging and Radiation Oncology</i> , <b>2014</b> , 58, 244-52	1.7	14
212	One-step radiosynthesis of 4-nitrophenyl 2-[[ $^{18}$ F]fluoropropionate ([[ $^{18}$ F]NFP); improved preparation of radiolabeled peptides for PET imaging. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , <b>2013</b> , 56, 726-30	1.9	14
211	Imaging in follicular NHL. <i>Best Practice and Research in Clinical Haematology</i> , <b>2011</b> , 24, 165-77	4.2	14
210	An approach to ventricular efficiency by use of carbon 11-labeled acetate and positron emission tomography. <i>Journal of Nuclear Cardiology</i> , <b>1994</b> , 1, 262-9	2.1	14
209	Assessment of myocardial oxidative metabolism in aortic valve disease using positron emission tomography with C-11 acetate. <i>American Heart Journal</i> , <b>1992</b> , 123, 653-64	4.9	14
208	What F-FDG PET Response-Assessment Method Best Predicts Survival After Curative-Intent Chemoradiation in Non-Small Cell Lung Cancer: EORTC, PERCIST, Peter Mac Criteria, or Deauville Criteria?. <i>Journal of Nuclear Medicine</i> , <b>2019</b> , 60, 328-334	8.9	13
207	The motivations and methodology for high-throughput PET imaging of small animals in cancer research. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2012</b> , 39, 1497-509	8.8	13

206	Should positron emission tomography/computed tomography be the first rather than the last test performed in the assessment of cancer?. <i>Cancer Imaging</i> , <b>2012</b> , 12, 315-23	5.6	13
205	Nuclear medicine techniques provide unique physiologic characterization of suspected and known soft tissue and bone sarcomas. <i>Acta Orthopaedica</i> , <b>1997</b> , 273, 25-36		13
204	Impact of PET on radiation therapy planning in lung cancer. <i>Radiologic Clinics of North America</i> , <b>2007</b> , 45, 627-38, v	2.3	13
203	Assessment of right ventricular oxidative metabolism by positron emission tomography with C-11 acetate in aortic valve disease. <i>American Journal of Cardiology</i> , <b>1991</b> , 67, 753-7	3	13
202	The Role of 68Ga-DOTA-Octreotate PET/CT in Follow-Up of SDH-Associated Pheochromocytoma and Paraganglioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2019</b> , 104, 5091-5099	5.6	12
201	The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of F-Fluoromethylcholine or Ga-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical Prostatectomy. <i>Journal of Nuclear Medicine</i> , <b>2019</b> , 60, 1253-1258	8.9	12
200	Modification of Biodistribution and Brain Uptake of Copper Bis(thiosemicarbazonato) Complexes by the Incorporation of Amine and Polyamine Functional Groups. <i>Inorganic Chemistry</i> , <b>2019</b> , 58, 4540-4552	5.1	12
199	Modifying the Poor Prognosis Associated with 18F-FDG-Avid NET with Peptide Receptor Chemo-Radionuclide Therapy (PRCRT). <i>Journal of Nuclear Medicine</i> , <b>2015</b> , 56, 968-9	8.9	12
198	Seduction by Sensitivity: Reality, Illusion, or Delusion? The Challenge of Assessing Outcomes after PSMA Imaging Selection of Patients for Treatment. <i>Journal of Nuclear Medicine</i> , <b>2017</b> , 58, 1969-1971	8.9	12
197	Metabolic imaging by positron emission tomography early after myocardial infarction as a predictor of recovery of myocardial function after reperfusion. <i>Journal of Nuclear Cardiology</i> , <b>1994</b> , 1, 124-37	2.1	12
196	F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Assessing Tumor Response to Immunotherapy in Solid Tumors: Melanoma and Beyond. <i>PET Clinics</i> , <b>2020</b> , 15, 11-22	2.2	12
195	International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. <i>Nature Reviews Endocrinology</i> , <b>2021</b> , 17, 435-444	15.2	12
194	Theranostic implications of molecular imaging phenotype of well-differentiated pulmonary carcinoid based on Ga-DOTATATE PET/CT and F-FDG PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2021</b> , 48, 204-216	8.8	12
193	Going nuclear: it is time to embed the nuclear medicine physician in the prostate cancer multidisciplinary team. <i>BJU International</i> , <b>2019</b> , 124, 551	5.6	11
192	PET-detected pneumonitis following curative-intent chemoradiation in non-small cell lung cancer (NSCLC): recognizing patterns and assessing the impact on the predictive ability of FDG-PET/CT response assessment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2019</b> , 46, 1869-1877	8.8	11
191	EORTC PET response criteria are more influenced by reconstruction inconsistencies than PERCIST but both benefit from the EARL harmonization program. <i>EJNMMI Physics</i> , <b>2017</b> , 4, 17	4.4	11
190	Respiratory-gated (4D) FDG-PET detects tumour and normal lung response after stereotactic radiotherapy for pulmonary metastases. <i>Acta Oncologica</i> , <b>2015</b> , 54, 1105-12	3.2	11
189	Lamina-specific changes in hippocampal GABA(A)/cBZR and mossy fibre sprouting during and following amygdala kindling in the rat. <i>Neurobiology of Disease</i> , <b>2009</b> , 35, 337-47	7.5	11

188	EEG dipole source localization of interictal spikes in non-lesional TLE with and without hippocampal sclerosis. <i>Epilepsy Research</i> , <b>2010</b> , 92, 183-90	3	11
187	PET tracer development--a tale of mice and men. <i>Cancer Imaging</i> , <b>2006</b> , 6, S102-6	5.6	11
186	Beyond FDG: novel PET tracers for cancer imaging. <i>Cancer Imaging</i> , <b>2003</b> , 4, 22-4	5.6	11
185	Positron emission tomography (PET): experience with a large-field-of-view three-dimensional PET scanner. <i>Medical Journal of Australia</i> , <b>1999</b> , 171, 529-32	4	11
184	Unmet needs in the international neuroendocrine tumor (NET) community: Assessment of major gaps from the perspective of patients, patient advocates and NET health care professionals. <i>International Journal of Cancer</i> , <b>2020</b> , 146, 1316-1323	7.5	11
183	Independent and incremental value of ventilation/perfusion PET/CT and CT pulmonary angiography for pulmonary embolism diagnosis: results of the PECAN pilot study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2019</b> , 46, 1596-1604	8.8	10
182	Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma. <i>Journal of Nuclear Medicine</i> , <b>2020</b> , 61, 1326-1330	8.9	10
181	Outcome of patients with early-stage follicular lymphoma staged with F-Fluorodeoxyglucose (FDG) positron emission tomography (PET) and treated with radiotherapy alone. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2019</b> , 46, 80-86	8.8	10
180	Enhanced white adipose tissue metabolism in iatrogenic Cushing's syndrome with FDG PET/CT. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2014</b> , 99, 3041-2	5.6	10
179	Preclinical FLT-PET and FDG-PET imaging of tumor response to the multi-targeted Aurora B kinase inhibitor, TAK-901. <i>Nuclear Medicine and Biology</i> , <b>2014</b> , 41, 148-54	2.1	10
178	Protracted hypocalcaemia following a single dose of denosumab in humoral hypercalcaemia of malignancy due to PTHrP-secreting neuroendocrine tumour. <i>Clinical Endocrinology</i> , <b>2014</b> , 81, 940-2	3.4	10
177	Clinical experience with the first combined positron emission tomography/computed tomography scanner in Australia. <i>Medical Journal of Australia</i> , <b>2005</b> , 182, 172-6	4	10
176	Positron emission tomography myocardial viability studies in patients with diabetes mellitus viability. <i>Journal of the American College of Cardiology</i> , <b>1991</b> , 17, A121	15.1	10
175	Routes of delivery for CpG and anti-CD137 for the treatment of orthotopic kidney tumors in mice. <i>PLoS ONE</i> , <b>2014</b> , 9, e95847	3.7	10
174	Hiatus hernia: a potential cause of false-positive iodine-131 scan in thyroid carcinoma. <i>Clinical Nuclear Medicine</i> , <b>1998</b> , 23, 621-2	1.7	10
173	Role of PET-CT in the Optimization of Thoracic Radiotherapy. <i>Journal of Thoracic Oncology</i> , <b>2006</b> , 1, 81-88.9	8.9	10
172	Diagnostic challenges in a patient with an occult insulinoma:Ga-DOTA-exendin-4 PET/CT and Ga-DOTATATE PET/CT. <i>Clinical Case Reports (discontinued)</i> , <b>2018</b> , 6, 719-722	0.7	9
171	Oligometastatic Renal Cell Carcinoma With Sarcomatoid Differentiation Demonstrating Variable Imaging Phenotypes on Ga-PSMA and F-FDG PET/CT: A Case Report and Review of the Literature. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> ,	3.3	9

170	Incremental diagnostic utility of gastric distension FDG PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2016</b> , 43, 644-53	8.8	9
169	[Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer - Author's reply. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, e373	21.7	9
168	A First-in-Human Study of Ga-Nanocolloid PET/CT Sentinel Lymph Node Imaging in Prostate Cancer Demonstrates Aberrant Lymphatic Drainage Pathways. <i>Journal of Nuclear Medicine</i> , <b>2018</b> , 59, 1837-1842	8.9	9
167	How can we tell if PET imaging for cancer is cost effective?. <i>Lancet Oncology, The</i> , <b>2010</b> , 11, 711-2	21.7	9
166	Role of functional imaging in head and neck squamous cell carcinoma: fluorodeoxyglucose positron emission tomography and beyond. <i>Hematology/Oncology Clinics of North America</i> , <b>2008</b> , 22, 1221-38, ix-x	3.1	9
165	Discordant response to chemotherapy detected by PET scanning: unveiling of a second primary cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2002</b> , 25, 368-70	2.7	9
164	Radiosynthesis of [123I]N-methyl-4-iododexetimide and [123I]N-methyl-4-iodolevetimide: in vitro and in vivo characterisation of binding to muscarinic receptors in the rat heart. <i>Nuclear Medicine and Biology</i> , <b>1996</b> , 23, 147-53	2.1	9
163	Differential effects of bisphosphonate on Paget's disease and metastatic prostatic carcinoma-bone scan findings. <i>Clinical Nuclear Medicine</i> , <b>2001</b> , 26, 347-8	1.7	9
162	Lung cancer. <i>PET Clinics</i> , <b>2015</b> , 10, 147-58	2.2	8
161	A New Theranostic Paradigm for Advanced Thyroid Cancer. <i>Journal of Nuclear Medicine</i> , <b>2016</b> , 57, 1493-1494	1.4	8
160	Dosimetric Consequences of 3D Versus 4D PET/CT for Target Delineation of Lung Stereotactic Radiotherapy. <i>Journal of Thoracic Oncology</i> , <b>2015</b> , 10, 1112-5	8.9	8
159	The role of positron emission tomography/computed tomography in planning radiotherapy in endometrial cancer. <i>International Journal of Gynecological Cancer</i> , <b>2015</b> , 25, 645-9	3.5	8
158	Tumour targeting of Auger emitters using DNA ligands conjugated to octreotate. <i>International Journal of Radiation Biology</i> , <b>2012</b> , 88, 1009-18	2.9	8
157	Imaging with F-18 FDG PET is superior to Tl-201 SPECT in the staging of non-small cell lung cancer for radical radiation therapy. <i>Journal of Medical Imaging and Radiation Oncology</i> , <b>2001</b> , 45, 483-90		8
156	Insulin-glucose clamp for standardization of metabolic conditions during F-18 fluoro-deoxyglucose pet imaging. <i>Journal of the American College of Cardiology</i> , <b>1991</b> , 17, A381	15.1	8
155	High-Specific-Activity-I-MIBG versus Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 2989-2995	12.9	8
154	Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma. <i>Investigational New Drugs</i> , <b>2020</b> , 38, 844-854	4.3	8
153	Citius, Altius, Fortius: An Olympian Dream for Theranostics. <i>Journal of Nuclear Medicine</i> , <b>2017</b> , 58, 194-195	1.9	7



152	Pharmacodynamic analysis of tumour perfusion assessed by 15O-water-PET imaging during treatment with sunitinib malate in patients with advanced malignancies. <i>EJNMMI Research</i> , <b>2012</b> , 2, 31	3.6	7
151	White fat, factitious hyperglycemia, and the role of FDG PET to enhance understanding of adipocyte metabolism. <i>EJNMMI Research</i> , <b>2011</b> , 1, 2	3.6	7
150	Sex and SUVmax: sex-dependent prognostication in early non-small cell lung cancer. <i>Journal of Nuclear Medicine</i> , <b>2012</b> , 53, 1676-85	8.9	7
149	Iodine-123 N-methyl-4-iododexetimide: a new radioligand for single-photon emission tomographic imaging of myocardial muscarinic receptors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>1995</b> , 22, 339-45		7
148	Bivalent Inhibitors of Prostate-Specific Membrane Antigen Conjugated to Desferrioxamine B Squaramide Labeled with Zirconium-89 or Gallium-68 for Diagnostic Imaging of Prostate Cancer. <i>Journal of Medicinal Chemistry</i> , <b>2020</b> , 63, 9258-9270	8.3	7
147	First clinical study of a pegylated diabody I-labeled PEG-AVP0458 in patients with tumor-associated glycoprotein 72 positive cancers. <i>Theranostics</i> , <b>2020</b> , 10, 11404-11415	12.1	7
146	Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 2: The Role of Novel PET Agents. <i>Journal of Nuclear Medicine</i> , <b>2020</b> , 61, 1553-1559	8.9	7
145	Amino acid-dependent signaling via S6K1 and MYC is essential for regulation of rDNA transcription. <i>Oncotarget</i> , <b>2016</b> , 7, 48887-48904	3.3	7
144	Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2019</b> , 46, 718-727	8.8	7
143	Voxel-wise correlation of positron emission tomography/computed tomography with multiparametric magnetic resonance imaging and histology of the prostate using a sophisticated registration framework. <i>BJU International</i> , <b>2019</b> , 123, 1020-1030	5.6	7
142	Sulfonation of Tyrosine as a Method To Improve Biodistribution of Peptide-Based Radiotracers: Novel F-Labeled Cyclic RGD Analogues. <i>Molecular Pharmaceutics</i> , <b>2017</b> , 14, 1169-1180	5.6	6
141	Wet or Dry? Do Liquid Biopsy Techniques Compete with or Complement PET for Disease Monitoring in Oncology?. <i>Journal of Nuclear Medicine</i> , <b>2017</b> , 58, 869-870	8.9	6
140	Cousins not twins: intratumoural and intertumoural heterogeneity in syndromic neuroendocrine tumours. <i>Journal of Pathology</i> , <b>2017</b> , 242, 273-283	9.4	6
139	Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns?. <i>Journal of Nuclear Medicine</i> , <b>2020</b> , 61, 1094-1095	8.9	6
138	Restaging: should we persist without pattern recognition?. <i>Journal of Nuclear Medicine</i> , <b>2010</b> , 51, 1830-28.9		6
137	Are health economics making us sick?. <i>Journal of Nuclear Medicine</i> , <b>2010</b> , 51, 1665-7	8.9	6
136	The risk of exaggerated risk aversion-a life and death struggle for molecular imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2009</b> , 36, 1693-4	8.8	6
135	The promise of PET in clinical management and as a sensitive test for drug cytotoxicity in sarcomas. <i>Expert Review of Molecular Diagnostics</i> , <b>2008</b> , 8, 105-19	3.8	6



134	A prospective study of the separate predictive capabilities of 18[F]-FDG-PET and molecular response in patients with relapsed indolent non-Hodgkin's lymphoma following treatment with iodine-131-rituximab radio-immunotherapy. <i>Haematologica</i> , <b>2008</b> , 93, 789-90	6.6	6
133	Ga-67 SPECT: ave atque vale! Or have we bid a premature farewell to a trusted friend?. <i>Leukemia and Lymphoma</i> , <b>2006</b> , 47, 2440-2	1.9	6
132	Inadvertent 2-deoxy-2-[18F]fluoro-D-glucose lymphoscintigraphy: a potential pitfall characterized by hybrid PET-CT. <i>Molecular Imaging and Biology</i> , <b>2002</b> , 4, 276-8	3.8	6
131	Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0.. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2022</b> , 49, 1386	8.8	6
130	Early Treatment Intensification with R-ICE Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) Using Zevalin-BEAM for Patients with Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) As Identified By Interim PET/CT Scan Performed after Four Cycles of R-CHOP-14: A Multicenter Phase II Study of the Australasian Leukaemia Lymphoma Study Group	2.2	6
129	Results of a 50 patient single-center phase II prospective trial of Lutetium-177 PSMA-617 theranostics in metastatic castrate-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2282-2288	2.2	6
128	The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology. <i>Nature Communications</i> , <b>2021</b> , 12, 5049	17.4	6
127	ENETS consensus guidelines for synoptic reporting of radiology studies. <i>Journal of Neuroendocrinology</i> , <b>2021</b> , e13044	3.8	6
126	Molecular Imaging of Recurrent and Metastatic Prostate Cancer. <i>Seminars in Nuclear Medicine</i> , <b>2019</b> , 49, 280-293	5.4	5
125	Synthesis and in Vivo Evaluation of [123I]Melanin-Targeted Agents. <i>Journal of Medicinal Chemistry</i> , <b>2015</b> , 58, 6214-24	8.3	5
124	The customer is always right, even when you are justifiably wrong. <i>Journal of Nuclear Medicine</i> , <b>2014</b> , 55, 1923-4	8.9	5
123	Preclinical characterization of 18F-D-FPHCys, a new amino acid-based PET tracer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2012</b> , 39, 703-12	8.8	5
122	Evaluation of a new visual uptake scoring scale for 18F-fluorothymidine positron emission tomography in the diagnosis of pulmonary lesions. <i>Nuclear Medicine Communications</i> , <b>2013</b> , 34, 521-6	1.6	5
121	Positron emission tomography and neoadjuvant therapy of breast cancer. <i>Journal of the National Cancer Institute Monographs</i> , <b>2011</b> , 2011, 111-5	4.8	5
120	What is the role of 18F-fluorodeoxyglucose positron emission tomography in mantle cell lymphoma?. <i>Leukemia and Lymphoma</i> , <b>2008</b> , 49, 1653-6	1.9	5
119	The evolving role of fluorodeoxyglucose positron emission tomography (FDG PET) in lymphoma: how do we reconcile conflicting results in the era of evidence-based medicine?. <i>Leukemia and Lymphoma</i> , <b>2006</b> , 47, 2008-10	1.9	5
118	Association between false negative hepatobiliary scans and initial gallbladder visualization after 30 min. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>1990</b> , 16, 747-53		5
117	Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma <b>2020</b> , 8,		5

116	Efficacy and safety of Lu-DOTATATE in lung neuroendocrine tumors: a bi-center study. <i>Journal of Nuclear Medicine</i> , <b>2021</b> ,	8.9	5
115	Molecular Imaging of Neuroendocrine Differentiation of Prostate Cancer: A Case Series. <i>Clinical Genitourinary Cancer</i> , <b>2021</b> , 19, e200-e205	3.3	5
114	Acute radiation oesophagitis associated with 2-deoxy-2-[18F]fluoro-d-glucose uptake on positron emission tomography/CT during chemo-radiation therapy in patients with non-small-cell lung cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , <b>2017</b> , 61, 682-688	1.7	4
113	Learning from Failure; Hypoxia Is an Evil Foe. <i>Journal of Nuclear Medicine</i> , <b>2017</b> , 58, 1043-1044	8.9	4
112	How we read: the combined use of MRI and novel PET tracers for the characterisation and treatment planning of masses in neuro-oncology. <i>Cancer Imaging</i> , <b>2019</b> , 19, 57	5.6	4
111	Personalised insulin calculator enables safe and effective correction of hyperglycaemia prior to FDG PET/CT. <i>EJNMMI Research</i> , <b>2019</b> , 9, 15	3.6	4
110	The role of F-FDG-PET/CT in evaluating retroperitoneal masses -Keeping your eye on the ball!. <i>Cancer Imaging</i> , <b>2019</b> , 19, 28	5.6	4
109	The evolving role of molecular imaging in non-small cell lung cancer radiotherapy. <i>Seminars in Radiation Oncology</i> , <b>2015</b> , 25, 133-42	5.5	4
108	Cerebrospinal Fluid Biomarkers are Differentially Related to Structural and Functional Changes in Dementia of the Alzheimer's Type. <i>Journal of Alzheimer's Disease</i> , <b>2018</b> , 62, 417-427	4.3	4
107	Strand breakage by decay of DNA-bound I provides a basis for combined PET imaging and Auger endoradiotherapy. <i>International Journal of Radiation Biology</i> , <b>2016</b> , 92, 686-697	2.9	4
106	Applying Advanced Imaging Techniques to a Murine Model of Orthotopic Osteosarcoma. <i>Frontiers in Surgery</i> , <b>2015</b> , 2, 36	2.3	4
105	Let's get SEERious: more accurate staging with consequent high management impact is not just stage migration. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 819	2.2	4
104	A dual radiologic contrast agent protocol for 18F-FDG and 18F-FLT PET/CT imaging of mice bearing abdominal tumors. <i>Molecular Imaging and Biology</i> , <b>2011</b> , 13, 518-525	3.8	4
103	Not-so-random errors: randomized controlled trials are not the only evidence of the value of PET. <i>Journal of Nuclear Medicine</i> , <b>2012</b> , 53, 1820-2; author reply 1822-1824	8.9	4
102	Scatter limitation to correct for arm movement in PET/CT. <i>Clinical Nuclear Medicine</i> , <b>2012</b> , 37, 786-7	1.7	4
101	Segmental hyperperfusion in lobar pneumonia visualized with respiratory-gated four-dimensional pulmonary perfusion positron emission tomography-computed tomography. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2014</b> , 189, 104-5	10.2	4
100	The utility of pharmacological and radiological interventions to optimize diagnostic information from PET/CT. <i>Cancer Imaging</i> , <b>2020</b> , 20, 68	5.6	4
99	Access, knowledge and experience with fluorodeoxyglucose positron emission tomography/computed tomography in infection management: a survey of Australia and New Zealand infectious diseases physicians and microbiologists. <i>Internal Medicine Journal</i> , <b>2019</b> , 49, 615-621	1.6	4

98	Early Outcomes of Surgery for Carcinoid Heart Disease. <i>Heart Lung and Circulation</i> , <b>2020</b> , 29, 742-747	1.8	4
97	Therapeutic Efficacy of a Bivalent Inhibitor of Prostate-Specific Membrane Antigen Labeled with Cu. <i>Journal of Nuclear Medicine</i> , <b>2021</b> , 62, 829-832	8.9	4
96	Automated preparation of 2-[F]fluoropropionate labeled peptides using a flexible, multi-stage synthesis platform (iPHASE Flexlab). <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , <b>2018</b> , 61, 61-67	1.9	4
95	ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours. <i>Journal of Neuroendocrinology</i> , <b>2021</b> , e13040	3.8	4
94	Role of PET-CT in the optimization of thoracic radiotherapy. <i>Journal of Thoracic Oncology</i> , <b>2006</b> , 1, 81-4	8.9	4
93	THYROPET Study: Is It Biology or Technology That Is the Issue?. <i>Journal of Nuclear Medicine</i> , <b>2017</b> , 58, 354	8.9	3
92	FDG-PET/CT in managing infection in patients with hematological malignancy: clinician knowledge and experience in Australia. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 2471-2476	1.9	3
91	Abscopal Regressions of Lymphoma After Involved-Site Radiation Therapy Confirmed by Positron Emission Tomography. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2020</b> , 108, 204-211	4	3
90	Carboplatin dosing in the era of IDMS-creatinine; the Cockcroft-Gault formula no longer provides a sufficiently accurate estimate of glomerular filtration rate for routine use in clinical care. <i>Gynecologic Oncology</i> , <b>2020</b> , 157, 793-798	4.9	3
89	Localisation of occult extra-pancreatic insulinoma using glucagon-like peptide-1 receptor molecular imaging. <i>Internal Medicine Journal</i> , <b>2018</b> , 48, 97-98	1.6	3
88	Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et al. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1221-3	2.2	3
87	STatistically Assigned Response Criteria in Solid Tumors (STARCISt). <i>Cancer Imaging</i> , <b>2015</b> , 15, 9	5.6	3
86	Breast lymphatic drainage via the pulmonary lymphatic system. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2010</b> , 37, 2203	8.8	3
85	PET for Therapeutic Response Monitoring in Oncology. <i>PET Clinics</i> , <b>2008</b> , 3, 89-99	2.2	3
84	The SUV and FLT PET: a tasty alphabet soup or a dog's breakfast?. <i>Leukemia and Lymphoma</i> , <b>2007</b> , 48, 649-52	1.9	3
83	Role of PET-CT in the Optimization of Thoracic Radiotherapy. <i>Journal of Thoracic Oncology</i> , <b>2006</b> , 1, 81-88	8.9	3
82	PSMA targeting in metastatic castration-resistant prostate cancer: where are we and where are we going?. <i>Therapeutic Advances in Medical Oncology</i> , <b>2021</b> , 13, 17588359211053898	5.4	3
81	T Cells in Merkel Cell Carcinomas Have a Proinflammatory Profile Prognostic of Patient Survival. <i>Cancer Immunology Research</i> , <b>2021</b> , 9, 612-623	12.5	3

80	An International Survey on Clinical Reporting of PET/CT Examinations: A Starting Point for Cross-Specialty Engagement. <i>Journal of Nuclear Medicine</i> , <b>2019</b> , 60, 480-485	8.9	3
79	Follow up results of a prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer. <i>Clinical and Translational Radiation Oncology</i> , <b>2017</b> , 2, 76-82	4.6	2
78	The Prognosis and Natural History of In-Transit Melanoma Metastases at a High-Volume Centre. <i>Annals of Surgical Oncology</i> , <b>2019</b> , 26, 4673-4680	3.1	2
77	Technical Note: Rapid multiexponential curve fitting algorithm for voxel-based targeted radionuclide dosimetry. <i>Medical Physics</i> , <b>2020</b> , 47, 4332-4339	4.4	2
76	The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose ( F) positron-emission tomography positive intermediate grade pancreatic neuroendocrine tumors. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2020</b> , 16, 150-157	1.9	2
75	The Injustice of Being Judged by the Errors of Others: The Tragic Tale of the Battle for PET Reimbursement. <i>Journal of Nuclear Medicine</i> , <b>2018</b> , 59, 418-420	8.9	2
74	Intense focal pituitary FDG uptake due to intravascular large B-cell lymphoma in pyrexia of unknown origin. <i>American Journal of Hematology</i> , <b>2016</b> , 91, 1167-1168	7.1	2
73	Association between radiation pneumonitis and tumor response in patients with NSCLC treated with chemoradiation. <i>Radiation Oncology</i> , <b>2014</b> , 9, 217	4.2	2
72	Imaging, radiation oncology and randomised trials: time for a change?. <i>Journal of Medical Imaging and Radiation Oncology</i> , <b>2011</b> , 55, 97-100	1.7	2
71	Using positron emission tomography to assess tumor proliferation in non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , <b>2010</b> , 51, 183-5	1.9	2
70	Cardiac blood-pool imaging in oncology more than an ejection fraction?. <i>Clinical Nuclear Medicine</i> , <b>2001</b> , 26, 18-26	1.7	2
69	Simulated bone metastases: a case study of two patients with breast cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , <b>1999</b> , 43, 365-8		2
68	Metabolic tumor burden for prediction of overall survival following combined BRAF/MEK inhibition in patients with advanced BRAF mutant melanoma.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 9006-9006	2.2	2
67	First in-human study of in vivo imaging of ex vivo labeled CAR T cells with dual PET-MR.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3557-3557	2.2	2
66	Managing radioiodine refractory thyroid cancer: the role of dosimetry and redifferentiation on subsequent I-131 therapy. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2020</b> , 64, 250-264	1.4	2
65	Utility of Ga-DOTA-Exendin-4 positron emission tomography-computed tomography imaging in distinguishing between insulinoma and nesidioblastosis in patients with confirmed endogenous hyperinsulinaemic hypoglycaemia. <i>Internal Medicine Journal</i> , <b>2021</b> , 51, 1657-1664	1.6	2
64	Safety and Efficacy of Ibrutinib in Combination with Venetoclax in Patients with Marginal Zone Lymphoma: Preliminary Results from an Open Label, Phase II Study. <i>Blood</i> , <b>2019</b> , 134, 3999-3999	2.2	2
63	Delayed Response After Confirmed Progression (DR) and Other Unique Immunotherapy-Related Treatment Concepts in Cutaneous Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 656611	5.3	2

62	A New Turn in Peptide-Based Imaging Agents: Foldamers Afford Improved Theranostics Targeting Cholecystokinin-2 Receptor-Positive Cancer. <i>Journal of Medicinal Chemistry</i> , <b>2021</b> , 64, 4841-4856	8.3	2
61	Cancer Diagnoses Following Abnormal Noninvasive Prenatal Testing: A Case Series, Literature Review, and Proposed Management Model. <i>JCO Precision Oncology</i> , <b>2021</b> , 5, 1001-1012	3.6	2
60	A new model for training in hybrid imaging. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 1152-1154	21.7	2
59	Re: palliative bypass for small bowel carcinoid with mesenteric mass and vascular encasement. <i>ANZ Journal of Surgery</i> , <b>2015</b> , 85, 197	1	1
58	Octreotide for resuscitation of cardiac arrest due to carcinoid crisis precipitated by novel peptide receptor radionuclide therapy (PRRT): A case report. <i>Journal of Critical Care</i> , <b>2020</b> , 60, 319-322	4	1
57	Complementary role of MRI and positron emission tomography in diagnosing cerebral abscess in a patient with metastatic paraganglioma. <i>Journal of Medical Imaging and Radiation Oncology</i> , <b>2018</b> , 62, 525	1.7	1
56	'Hot spot' cardiac ischemia imaging with fluorodeoxyglucose positron emission tomography. <i>Journal of Nuclear Cardiology</i> , <b>2016</b> , 23, 1514-1517	2.1	1
55	Characterizing high-grade serous papillary carcinoma of tunica vaginalis. <i>Urology Case Reports</i> , <b>2019</b> , 26, 100949	0.5	1
54	Longitudinal Partial Volume Correction in 2-[18F]-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Studies of Alzheimer Disease. <i>Journal of Computer Assisted Tomography</i> , <b>2015</b> , 39, 559-64	2.2	1
53	Reply to G. Keramida et al. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4121-2	2.2	1
52	. <i>Clinical and Translational Imaging</i> , <b>2014</b> , 2, 5-12	2	1
51	Not-so-random errors: randomized controlled trials are not the only evidence of the value of PET--rebuttal. <i>Journal of Nuclear Medicine</i> , <b>2013</b> , 54, 492	8.9	1
50	Time and again, children resemble their parents. <i>Journal of Nuclear Medicine</i> , <b>2008</b> , 49, 1577-8	8.9	1
49	Impact of PET on Radiation Therapy Planning. <i>PET Clinics</i> , <b>2006</b> , 1, 317-28	2.2	1
48	F-18 PET soft tissue uptake in seatbelt injury. <i>Clinical Nuclear Medicine</i> , <b>2004</b> , 29, 809-10	1.7	1
47	Surgery for primary hyperparathyroidism 1962-1996: Indications and outcomes. <i>Medical Journal of Australia</i> , <b>1998</b> , 169, 118-119	4	1
46	PET/CT variants and pitfalls in malignant melanoma. <i>Cancer Imaging</i> , <b>2022</b> , 22, 3	5.6	1
45	Perspective paper about the joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[F]FDG-PET/CT external beam radiation treatment planning in lung cancer. <i>Radiotherapy and Oncology</i> , <b>2022</b> ,	5.3	1

44	Automated preparation of clinical grade [Ga]Ga-DOTA-CP04, a cholecystokinin-2 receptor agonist, using iPHASE MultiSyn synthesis platform. <i>EJNMMI Radiopharmacy and Chemistry</i> , <b>2019</b> , 4, 23	5.8	1
43	Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 9563-9563	2.2	1
42	Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): Interim results of a phase II trial.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 5040-5040	2.2	1
41	The ProPSMA Study[Clinical trial protocol: A prospective randomized multi-center study of the impact of Ga-68 PSMA PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, TPS138-TPS138	2.2	1
40	Access to diagnostics and treatment of neuroendocrine tumors (NETs): The difference between patient perception and reality. <b>2019</b> , 5, 6-6		1
39	[ <sup>18</sup> F]Fluoro Azomycin Arabinoside ([ <sup>18</sup> F]FAZA): Synthesis, Radiofluorination and Preliminary PET Imaging of Murine A431 Tumors. <i>Current Radiopharmaceuticals</i> , <b>2017</b> , 10, 93-101	1.8	1
38	FDG-PET/CT imaging for evaluating durable responses to immune check point inhibitors in patients with advanced cutaneous squamous cell carcinoma. <i>Cancer Imaging</i> , <b>2021</b> , 21, 57	5.6	1
37	Adaptive post-transcriptional reprogramming of metabolism limits response to targeted therapy in BRAFV600 melanoma		1
36	Pitfalls and Immune-Related Adverse Events <b>2020</b> , 101-115		1
35	Back to the Future: Nuclear Medicine Rediscovered Its Therapeutic Roots <b>2016</b> , 277-287		1
34	Imaging Somatostatin Positive Tumors with Tyr-Octreotate/Octreotide Conjugated to Desferrioxamine B Squaramide Radiolabeled with either Zirconium-89 or Gallium-68. <i>Bioconjugate Chemistry</i> , <b>2021</b> , 32, 1192-1203	6.3	1
33	Intra-patient comparison of physiologic Ga-PSMA-11 and F-DCFPyL PET/CT uptake in ganglia in prostate cancer patients: a pictorial essay. <i>Cancer Imaging</i> , <b>2021</b> , 21, 35	5.6	1
32	Short and long-term prognostic implications of a low embolic burden in oncology patients diagnosed with symptomatic pulmonary embolism. <i>Annals of Hematology</i> , <b>2016</b> , 95, 651-2	3	1
31	Radiosynthesis and preliminary in vivo evaluation of <sup>18</sup> F-labelled glycosylated duramycin peptides for imaging of phosphatidylethanolamine during apoptosis. <i>MedChemComm</i> , <b>2019</b> , 10, 1930-1934	5	1
30	Nodal metabolic tumour volume on baseline F-FDG PET/CT and overall survival in stage II and III NSCLC patients undergoing curative-intent chemoradiotherapy/radiotherapy. <i>Journal of Medical Imaging and Radiation Oncology</i> , <b>2021</b> , 65, 748-754	1.7	1
29	Novel RET Fusion Predicts Response to Selective RET Inhibition With Selpercatinib in Malignant Pheochromocytoma.. <i>JCO Precision Oncology</i> , <b>2021</b> , 5, 1160-1165	3.6	1
28	Enzyme mediated incorporation of zirconium-89 or copper-64 into a fragment antibody for same day imaging of epidermal growth factor receptor. <i>Chemical Science</i> , <b>2021</b> , 12, 9004-9016	9.4	1
27	Primary Bone Tumors <b>2006</b> , 267-301		1



26	A Bivalent Inhibitor of Prostate Specific Membrane Antigen Radiolabeled with Copper-64 with High Tumor Uptake and Retention. <i>Angewandte Chemie</i> , <b>2019</b> , 131, 15133-15136	3.6	o
25	Longitudinal changes of focal cortical glucose hypometabolism in adults with chronic drug resistant temporal lobe epilepsy. <i>Brain Imaging and Behavior</i> , <b>2021</b> , 1	4.1	o
24	Intratumoral T-cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B-cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R-CHOP) chemoimmunotherapy. <i>Clinical and Translational Immunology</i> , <b>2021</b> , 10, e1351	6.8	o
23	Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAF melanoma.. <i>Nature Communications</i> , <b>2022</b> , 13, 1100	17.4	o
22	Imaging immunity in patients with cancer using positron emission tomography.. <i>Npj Precision Oncology</i> , <b>2022</b> , 6, 24	9.8	o
21	The value of the Standardized Uptake Value (SUV) and Metabolic Tumor Volume (MTV) in lung cancer. <i>Seminars in Nuclear Medicine</i> , <b>2022</b> ,	5.4	o
20	Role of PET/CT in Melanoma <b>2017</b> , 37-51		
19	PET/CT in Melanoma (Additional Teaching Cases) <b>2017</b> , 53-63		
18	PET and PET/CT in Treatment Planning. <i>Medical Radiology</i> , <b>2011</b> , 173-186	0.2	
17	Incidental findings on follow-up fluorodeoxyglucose positron emission tomography studies in lymphoma patients: beware the outlier. <i>Leukemia and Lymphoma</i> , <b>2009</b> , 50, 865-7	1.9	
16	The impact of PET-CT in suspected recurrent ovarian cancer: A prospective multi-centre study as part of the Australian PET Data Collection Project: Response to a letter from Dr. Maurie Markman. <i>Gynecologic Oncology</i> , <b>2009</b> , 114, 536-537	4.9	
15	In Reply to Dr. Faraci and Colleagues. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2008</b> , 72, 304	4	
14	PET Scanning in Staging and Evaluation of Response to Treatment in Lung Cancer <b>2005</b> , 461-471		
13	On the Inclusion of Specialists as Authors in Systematic Reviews. <i>SpringerBriefs in Ethics</i> , <b>2020</b> , 57-66	0.1	
12	Combining radionuclide therapy with radiotherapy <b>2021</b> ,		
11	Non-small Cell Lung Carcinoma <b>2008</b> , 237-247		
10	A randomized trial comparing fluorocholine-PET/CT with conventional imaging in prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2-2	2.2	
9	Access to diagnostics and treatment of neuroendocrine tumors (NETs): The difference between patient perception and reality.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e13524-e13524	2.2	

- 8 Clinical and FDG-PET markers of immune checkpoint inhibitor (ICI) response in patients with metastatic Merkel cell carcinoma (mMCC).. *Journal of Clinical Oncology*, **2019**, 37, 9540-9540 2.2
- 7 FDG-PET metabolic tumor volume in advanced melanoma treated with ipilimumab and nivolumab (ipi/nivo).. *Journal of Clinical Oncology*, **2020**, 38, 10041-10041 2.2
- 6 PERCISTence: Strength or Stubbornness?. *Journal of Nuclear Medicine*, **2020**, 61, 199S-200S 8.9
- 5 Breast Cancer: Role of Planar, SPECT and PET in Imaging Bone Metastases **2012**, 661-689
- 4 Radionuclide imaging of NENs. *Current Opinion in Endocrine and Metabolic Research*, **2021**, 18, 207-215 1.7
- 3 Molecular imaging with FLT: a case of Cassandra's curse?. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 2687-2689 8.8
- 2 Gallium-68 Ventilation/Perfusion PET-CT and CT Pulmonary Angiography for Pulmonary Embolism Diagnosis: An Interobserver Agreement Study. *Frontiers in Medicine*, **2020**, 7, 599901 4.9
- 1 PET Diagnosis and Response Monitoring in Oncology **2021**, 1049-1076